Clinical Trial

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-02-12; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2024-03-14
Trial Details
NCT Number NCT06265727
Lead Sponsor Corbus Pharmaceuticals Inc.
Collaborators: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions Solid Tumor, Adult
Enrollment 348 participants
Start Date 2024-04-01
Primary Completion 2027-01-16 (estimated)
Study Completion 2027-01-27 (estimated)
Updated on ClinicalTrials.gov 2026-01-08